CurrentCignaPolicy N/A

Cinacalcet Prior Authorization Policy

Defines prior authorization requirements and coverage criteria for cinacalcet (Sensipar and generic) for Cigna-administered health benefit plans, specifying indications, prescriber qualifications, and duration of approvals.

Policy Summary

PayerCigna

PolicyCinacalcet Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document baseline iPTH/calcium and specialist prescriber or consultation; approvals are provided for 1 year.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4distinct covered indications listed

1 yearstandard approval duration

≥2x ULNiPTH baseline requirement

Specialist requiredspecialist prescriber required

NCapplicable state

Coverage Criteria for Cinacalcet (Sensipar)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Covered indications / Medical necessity

Sensipar (cinacalcet) is covered as medically necessary when criteria below for the indicated condition are met.

Covered Indications

Parathyroid carcinoma: Hypercalcemia due to parathyroid carcinoma
Approve for 1 year if cinacalcet is prescribed by or in consultation with an oncologist or endocrinologist.
Primary hyperparathyroidism (non-surgical candidate): Hypercalcemia in primary hyperparathyroidism when BOTH A and B are met: A) patient has failed or is unable to undergo a parathyroidectomy due to a contraindication; AND B) the medication is prescribed by or in consultation with a nephrologist or endocrinologist
Approve for 1 year; parathyroidectomy remains primary treatment.
Secondary hyperparathyroidism (CKD on dialysis): Secondary hyperparathyroidism when ALL A-D are met: A) patient has chronic kidney disease; AND B) patient is on dialysis; AND C) baseline intact parathyroid hormone (iPTH) is ≥ 2 × upper limit of normal measured on two separate occasions; AND D) the medication is prescribed by or in consultation with a nephrologist or endocrinologistiPTH ≥ 2× ULN on two occasions
Approve for 1 year.

Sensipar® (cinacalcet) is considered not medically necessary for any uses not expressly listed as covered in this policy. Specifically, cinacalcet is not medically necessary for patients with primary hyperparathyroidism who are eligible for parathyroidectomy, as parathyroidectomy is the primary indicated treatment for primary hyperparathyroidism.

Use of cinacalcet for any indication not specified in this policy is considered not medically necessary. Requests for coverage for unspecified indications will be evaluated against the policy’s covered indications and will be denied when they do not meet those criteria.

Coding, Definitions, and Baseline Requirements

iPTH baseline requirement

iPTH baseline requirementIntact parathyroid hormone (iPTH) ≥ two times the upper limit of normal (per laboratory reference) measured on two separate occasions before initiating therapy

Measurement timingTwo separate occasions prior to starting cinacalcet therapy

Reference standardUse laboratory-specific ULN to determine 2x threshold

Secondary hyperparathyroidism

DefinitionSecondary hyperparathyroidism is a common complication of chronic kidney disease (CKD) characterized by reduced circulating calcitriol and disturbances in calcium and phosphorus metabolism leading to elevated PTH levels

Clinical consequenceElevated PTH drives increased osteoclastic activity, bone resorption, and marrow fibrosis

Policy contextCinacalcet is indicated for secondary hyperparathyroidism in adults on dialysis

Indication limitation — CKD (non-dialysis)

Indication limitationCinacalcet is not indicated for patients with CKD who are not on dialysis due to an increased risk of hypocalcemia

Applicable populationLimitation applies to CKD patients not receiving dialysis

Implication for coverageRequests for cinacalcet in non-dialysis CKD patients are excluded based on this contraindication-related risk

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required/recommended for cinacalcet (Sensipar®); approvals are provided for the duration noted below. Because evaluation and monitoring require specialized skills, cinacalcet must be prescribed by or in consultation with a specialist in the treated condition.

Prior authorization recommended for prescription benefit coverage; approvals provided for the durations specified in indications.
Prescriber specialty requirement: must be prescribed by or in consultation with an oncologist, endocrinologist, nephrologist, or transplant physician as specified by indication.

Note

Surgery Prerequisite for Primary Hyperparathyroidism

Parathyroidectomy is the primary treatment for primary hyperparathyroidism. Coverage of cinacalcet for primary hyperparathyroidism is conditional on documented failure of surgery or documented contraindication/inability to undergo parathyroidectomy.

For primary hyperparathyroidism: approve for 1 year only if patient has failed or is unable to undergo parathyroidectomy due to a contraindication.
Document surgical ineligibility or prior failed surgery in the medical record.

Documentation Required

Required Documentation

Document the clinical and laboratory evidence supporting therapy. Provide baseline and follow-up data, specialty consult notes, and surgical evaluation when applicable.

Required labs: baseline intact parathyroid hormone (iPTH) and serum calcium prior to initiation; for secondary hyperparathyroidism, iPTH must be ≥2× upper limit of normal on two separate occasions.
Required documentation: specialty prescriber or consult (nephrology, endocrinology, oncology, or transplant as indicated), notes confirming dialysis status for secondary hyperparathyroidism, and evidence of parathyroidectomy failure or contraindication for primary hyperparathyroidism.
Approval duration: typically approved for 1 year per indication; include rationale and plan for ongoing monitoring in requests.

Denial Risk

Denial Triggers / Not Medically Necessary Uses

Requests will be denied if criteria are not met or if use is not medically necessary for the listed indications.

Denial triggers include: patient with primary hyperparathyroidism who is eligible for and has not failed or been contraindicated for parathyroidectomy.
Denial for any uses not supported by the policy (i.e., indications other than those listed or lacking supportive evidence).
Insufficient documentation of baseline iPTH/calcium, dialysis status (when required), or lack of specialist consultation may result in denial.

Background

Cinacalcet is a calcimimetic that acts as a positive allosteric modulator of the calcium-sensing receptor on parathyroid cells, lowering parathyroid hormone (PTH) secretion and reducing serum calcium. It is indicated for hypercalcemia due to parathyroid carcinoma, for primary hyperparathyroidism when surgery is not possible or has failed, and for secondary hyperparathyroidism in adults on dialysis. In CKD-related secondary hyperparathyroidism, disturbances in calcium, phosphate, and calcitriol lead to elevated PTH and bone disease; cinacalcet lowers PTH and can help control hypercalcemia in these contexts.